StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) to a sell rating in a research report released on Friday morning.
RGLS has been the topic of a number of other research reports. HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, August 9th. Oppenheimer reissued an outperform rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. Finally, Canaccord Genuity Group upped their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a buy rating in a report on Tuesday, June 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $10.80.
Check Out Our Latest Stock Analysis on RGLS
Regulus Therapeutics Stock Performance
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics during the second quarter worth $136,000. Renaissance Technologies LLC grew its holdings in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares during the period. Victory Capital Management Inc. raised its position in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth about $352,000. Finally, Opaleye Management Inc. acquired a new position in shares of Regulus Therapeutics in the 1st quarter valued at about $490,000. Institutional investors own 92.38% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Further Reading
- Five stocks we like better than Regulus Therapeutics
- What is the FTSE 100 index?
- Why Block’s Key Components Make It a Solid Investment Choice
- What is Insider Trading? What You Can Learn from Insider Trading
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Top Biotech Stocks: Exploring Innovation Opportunities
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.